Deborah Blythe Doroshow

Dr. Deborah Blythe Doroshow

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cancer Cell
Verified
Journal Article
Closed access
ASAndrew L. Schmidt
Andrew L. Schmidt
ZBZiad Bakouny
Ziad Bakouny
SBSheena Bhalla
Sheena Bhalla
JSJohn A. Steinharter
John A. Steinharter
DTDouglas A. Tremblay
Douglas A. Tremblay
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow

26 August 2021 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow
WWWei Wei
Wei Wei
SGSwati Gupta
Swati Gupta
JZJon Zugazagoitia
Jon Zugazagoitia
CRCharles Robbins
Charles Robbins
DRDavid L. Rimm
David L. Rimm

14 June 2022 in Annals of Oncology
Verified
Journal Article
Closed access
ZBZ. Bakouny
Z. Bakouny
CLC. Labaki
C. Labaki
SBS. Bhalla
S. Bhalla
ASA.L. Schmidt
A.L. Schmidt
JSJ.A. Steinharter
J.A. Steinharter
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow

18 August 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow
SPScott Podolsky
Scott Podolsky
JBJustin Barr
Justin Barr
COVID-19 has disrupted the lives of billions of people worldwide. Emergencies can stimulate substantial investment of resources that catalyze impressive scientific accomplishments but can also lead... Coronavirus disease 2019 (COVID-19) has sickened millions, killed hundreds of thousands, and utterly disrupted the daily lives of billions of people around the world. In an effort to ameliorate thi...

1 November 2020 in The Cancer Journal
Verified
Journal Article
Closed access
SBSheena Bhalla
Sheena Bhalla
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow
FHFred R. Hirsch
Fred R. Hirsch
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for advanced non–small cell lung cancer (NSCLC). Although certain patients achieve significant, long-lasting responses from checkpoint blockade, the majority of patients with NSCLC do not and may be unnecessarily exposed to inadequate therapies and immune-related toxicities. Therefore, there is a critical need to identify biomarkers predictive of immunotherapy response. While tumor and immune cell expression of programmed death ligand-1 and, more recently, tumor mutational burden are used in clinical practice and may correlate with immunotherapy response in selected circumstances, neither consistently predicts an individual patient's likelihood of clinical benefit from ICI therapy. More recently, innovative approaches such as blood-based assays and combination biomarker strategies are under active investigation. This review will focus on the current role and challenges of programmed death ligand-1 and tumor mutational burden as predictive biomarkers for immunotherapy response in advanced NSCLC and explore promising novel biomarker strategies.

8 January 2021 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
JBJustin Barr
Justin Barr
RMRichard A. McKay
Richard A. McKay
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow